MITONCO 10mg Price

Overview

Welcome to Dwaey, specifically on MITONCO 10mg page.
This medicine contains an important and useful components, as it consists of
Mitomycinis available in the market in concentration

Name

Mitomycin

Precaution

Patient w/ bone marrow depression, infections including varicella infection. Hepatic or renal impairment. Patient Counselling This drug may cause generalised weakness and lethargy, if affected, do not drive or operate machinery. Monitoring Parameters Repeated haematologic studies (platelet count, leukocyte count, differential, prothrombin time, bleeding time and Hb determinations) are necessary during therapy and for at least 7 wk following discontinuance of the drug. Carefully monitor LFTs and renal function test. Lactation: Not known if excreted in breast milk, do not nurse

Indication

Solid tumours, non-invasive bladder cancer, stomach cancer, pancreas cancer, metastatic breast cancer, advanced cervical cancer, anal carcinoma

Contra indication

Hypersensitivity. Patient w/ platelet counts <100,000/mm3, leukocyte counts <4,000/mm3 or serum creatinine concentration >1.7 mg/dL. Patient w/ substantial prolongation of prothrombin time or bleeding time, coagulation disorders, increased bleeding tendency. Pregnancy and lactation.

Side Effect

>10% Hemolytic uremic syndrome (?15%),Myelosuppression (64%),Nausea/vomiting (14%),Fever (14%) 1-10% Stomatitis (4%),Increased serum creatinine (2%),Mucous membrane toxicity (4%) Frequency Not Defined Fatigue,Pulmonary toxicity,Dyspnea,Cystitis,Interstitial fibrosis,Nephrotoxicity,Amenorrhea,Alopecia Potentially Fatal: Myelosuppression, haemolytic-uraemic syndrome.

Pregnancy Category ID

4

Mode of Action

Mitomycin is an antineoplastic antibiotic which is enzymatically reduced to its active metabolite w/in susceptible cells. The active metabolite appears to cause cross-linking of DNA (primarily w/ guanine and cytosine pairs). It is also active against gm+ve bacteria and some viruses.

Interaction

Increased incidence of cardiotoxicity w/ doxorubicin. Potentially Fatal: Increased risk of intravascular haemolysis and renal failure w/ fluorouracil. Increased risk of haemolytic uraemic syndrome w/ tamoxifen. Acute pulmonary toxicity w/ vinca alkaloids (e.g. vinblastine, vinorelbine). Increased bone marrow depressant effects of aclarubicin.

Pregnancy Category Note

Information not available

Adult Dose

Child Dose

Renal Dose

Administration